OTC · JNHMF
Jack Nathan Medical Corp.
$0.00$0.00 (0.0%)
Jack Nathan Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
Loading market information…
OTC · AVXT · USD
Stock price
Quote as of Dec 30, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AVAX Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer. Established in 1990, the Philadelphia, Pennsylvania-based entity initially operated as Walden Laboratories, Inc. before adopting its current name, AVAX Technologies, Inc., in March 1996.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Jack Nathan Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
$0.00$0.00 (0.0%)
Mobile Lads Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Item 9 Labs Corp.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
South American Gold Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (-50.0%)
U.S. Stem Cell, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Mera Pharmaceuticals, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Braxia Scientific Corp.’s quoted price sits in the lower half of its reported 52-week range, 92.19% below the high.
$0.00$0.00 (0.0%)
DNAPrint Genomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
